514 Results of Phase 1b trial of the Indoleamine 2, 3-dioxygenase (IDO) Pathway Inhibitor Indoximod plus Ipilimumab for the treatment of unresectable stage III or IV melanoma. (September 2015) - Zakharia, Y.; Drabick, J.; Khleif, S.; Munn, D.; Link, C.; Vahanian, N.; Kennedy, E.; Rixe, O.; Milhem, M.